The incidence of colorectal cancer in the mainland is increasing year by year, and data from the World Health Organization's International Agency for Research on Cancer (IARC) shows that the number of new cases of colorectal cancer in China in 2020 has reached 560,000, and the number of deaths due to colorectal cancer has reached 290,000.
Although the data on morbidity and mortality are staggering, early screening and prevention of colorectal cancer can greatly reduce the incidence and improve the cure rate. The Xinghuo Project Guangjiyuan Academic Week Colorectal Cancer Diagnosis and Treatment Salon allows well-known clinical experts in the field of colorectal cancer to gather on the cloud and exchange the latest clinical progress and academic research online through the Network.
At the opening of the meeting, Professor Sun Lifeng of the Second Affiliated Hospital of Zhejiang University School of Medicine opened his speech, welcoming all of you and thanking Nanjing Chia Tai Tianqing for providing a platform. At the same time, Professor Sun combined his rich clinical experience, shared his experience in colorectal cancer treatment, and summarized the agenda and content of the conference.
Subsequently, Professor Zhang Xiaochen of the First Affiliated Hospital of Zhejiang University School of Medicine made a speech at the meeting, pointing out the current diagnosis and treatment status and pain points of colorectal cancer, sorting out the treatment direction of colorectal cancer diseases in the future, and wishing the meeting a complete success.
The conference was divided into two stages, the first stage was chaired by Professor Qiu Hong of Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology to conduct academic sharing in the field of colon cancer, and the second stage was chaired by Professor Zeng Shan of Xiangya Hospital of Central South University, and the speakers shared and discussed colorectal cancer cases.
In the first phase of academic sharing, Professor Chen Yigui of Fujian Cancer Hospital introduced the overview and situation of colorectal cancer treatment with the theme of "Application of Raltex race in colorectal cancer", and introduced the mechanism and advantages of raltexed. Professor Chen compared raltetrexed with similar products such as 5-fluorouracil in detail, and used evidence-based medical evidence to prove that raltetrexed is safe in cardiotoxicity. Professor Chen also put forward the thinking and confusion of the current second-line treatment.
Professor Zhao Peng's project at the First Affiliated Hospital of Zhejiang University School of Medicine is "2021 Colorectal Cancer Immunotherapy Year-end Inventory". Professor Zhao explained the different treatment options of colorectal cancer in the sharing, integrated the program guidance of NCCN and CSCO guidelines, and combined with specific research, clearly pointed out the efficacy and advantages of immunotherapy in the treatment of colorectal cancer, and also put forward the development and thinking direction of immunotherapy in the field of colorectal cancer. On this basis, Professor Zhao Peng also specifically pointed out the main point of the future development and progress of colorectal cancer from 5 directions.
After the two speakers finished sharing, they entered the discussion session, and in this session, the participating experts also expressed their views. Professor Qiu Hong said that the sharing of Immunotherapy between Professor Chen and Professor Zhao is very appropriate, and it can also bring new thinking and direction to clinical treatment.
Professor Huang Chenghui of the Third Xiangya Hospital of Central South University said that the clinical coverage and clinical performance of raltetrexed are good, the efficiency is higher than that of 5-fluorouracil, and the performance is safer and more effective in liver function and gastrointestinal response. Professor Huang also suggested that in future clinical practice, more data related to raltetrexed heat perfusion can be collected.
Professor Xiao Li of Zhongshan Hospital Affiliated to Xiamen University has a profound experience in the use of raltitrexed. Professor Xiao believes that in terms of cardiotoxicity, raltitrexed has the advantage of authoritative guidelines; for patients with bowel cancer, raltitrexed is an adjustment strategy; for special patients, such as liver metastases, raltitrexed has a good effect as hepatic artery perfusion chemotherapy; peritoneal metastases have a good effect, and there are also guideline recommendations.
Professor Lin Xiaoji of the Second Affiliated Hospital of Wenzhou Medical College said that with the progress and iteration of research and development, the replacement of tumor treatment drugs is also very fast. Professor Lin believes that there are obvious advantages in the use of single drugs and combination use of raltetrexed, including fewer adverse reactions. As a second-line drug therapy, it can effectively improve the prognosis, and whether this advantage can be superimposed with the advantage of targeted drugs in the later stage needs further clinical research and exploration.
Professor Chen Wen of the Second Affiliated Hospital of Fujian Medical University combined with more than ten years of clinical experience, raltetrexed is used for the first-line treatment of elderly patients with underlying heart disease, and will also be used in the 3rd line. Professor Chen said that the use of latitrexed in the first line is good. At the same time, Professor Chen raised questions about the dosage of intraperitoneal perfusion administration. In response to this question, Professor Xiao Li suggested that the dosage and intravenous use are the same, and the treatment effect of this medication is better according to the lowest dose. Professor Sun Lifeng also said that relevant experiments have proved that 2~5mg/mL doses can be used, and suggested that small doses are safer and more effective.
The discussion session ends and the second phase is the case sharing session. The case sharing brought by the speakers more effectively demonstrated the advantages of the clinical application and combination of raltetrexed.
The first case was a case of liver metastasis of colorectal cancer shared by Professor Li Jianjiong of Ningbo Huamei Hospital of the University of Chinese Academy of Sciences.
Patient: 68 years old, presented for "change in stool habits for more than 1 year", enhanced MRI and PET-CT tests showed concomitant liver metastasis of colon cancer, staged: CT4N0M1, liver: 1 metastase, initially resectable CRS.
After the first MDT diagnosis of bowel cancer liver metastasis, can be resected in stages, in May 2021 resection of rectal cancer radical resection, postoperative patients with abnormal cardiac pointer, using oxaliplatin + retidrexed after 2 cycles of chemotherapy in August 2021 under laparoscopic liver cancer resection, postoperative oxaliplatin + retidetroxed continued treatment for 6 cycles; in 2021, patients were admitted to the hospital for the second MDT due to liver discomfort, diagnosed as multiple liver metastases, difficult to treat surgically, FOLFIRI chemotherapy program for translational treatment.
The patient is currently in stable condition.
The second case was a case of advanced bowel cancer shared by Professor Tan Yinuo of the Second Affiliated Hospital of Zhejiang University School of Medicine.
Patients: Male, 33 years old for rectal cancer surgery more than 3 years after surgery, more than 3 months after brain metastases surgery, his condition is complex, after radical resection of colorectal cancer in 2019, lung, liver, and brain metastases from May 2020 to September 2021.
The patient's condition is complex, raltetrexed is used in the back line therapy, the effect is still very ideal, the patient reaches PR after 2 cycles.
In response to these two cases, Professor Fu Jianfei of Jinhua Central Hospital, Professor Chen Shengchi of Nanping First Hospital, Professor Lin Zhenyu of Union Hospital Affiliated to Huazhong University of Science and Technology, and Professor Mao Chenyu of the First Affiliated Hospital of Zhejiang University School of Medicine made comments and fierce discussions.
Finally, Professor Yuan Ying of the Second Affiliated Hospital of Zhejiang University School of Medicine made a summary of the meeting. Professor Yuan said: The clinical use of raltetrexed is very convenient, which can improve the turnover rate of the hospital bed and is a good choice for medication. At the end of the meeting, Professor Yuan expressed his gratitude to the speakers, moderators and discussors attending the meeting, and thanked Nanjing Chia Tai Tianqing Company for providing such a platform for everyone.
Professor Yuan said: Cancer patients have a complex condition, but fortunately, with the development of new drugs and the emergence of new therapies, patients also have more possibilities to survive. At the same time, Professor Yuan specially called on more than 20 experts attending the meeting online to speak out on the current problem of limited reimbursement of medical insurance with Beva Lianlei!